Document is current
Any future updates will be listed below
-
Authors
Tamaki, Junko https://orcid.org/0000-0003-3930-9729
Ogawa, Sumito
Fujimori, Kenji
Ishii, Shigeyuki
Nakatoh, Shinichi
Okimoto, Nobukazu
Kamiya, Kuniyasu
Iki, Masayuki
-
Funding
Funding for this research was provided by:
Taiju Life Social Welfare Foundation (a 52nd Taiju Life Social Welfare Foundation Medical Research Grant 2019)
Japan Osteoporosis Foundation (a Japan Osteoporosis Foundation Grant for Bone Research 2019)
Pfizer Japan (a 28th Pfizer Health Research Grant 2019)
- License Information
-
More Information
Article History
Received: 1 June 2022
Accepted: 20 September 2022
First Online: 14 December 2022
Declarations
:
: Shigeyuki Ishii has received written manuscripts fees for Asahi Kasei Pharma Ltd. and honorarium from Teijin Pharma Ltd.. Shinichi Nakatoh has received payments for lectures, speakers’ bureau fees from Asahi-Kasei Pharmaceutical Co. Ltd., Amgen K. K. and Astellas Pharma Inc.. Nobukazu Okimoto has received honoraria for lectures from Asahi-Kasei Pharmaceutical Co. Ltd., Amgen Astellas Biopharma K.K., Astellas Pharma Inc., Chugai Pharmaceutical Co., Daiichi-Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan, and Teijin Pharma Ltd.. Junko Tamaki, Sumito Ogawa, Kenji Fujimori, Kuniyasu Kamiya and Masayuki Iki declare that they have no conflicts of interest.
